With a 650,000 euro funding from ZonMw, researchers from the Haematology and Pharmacy departments can develop a medication phasing out strategy for patients with chronic myeloid leukaemia. This strategy will be tested in practice.
Chronic myeloid leukaemia (CML) is a serious and rare disease. With new, expensive drugs (tyrosine kinase inhibitors), patients can be treated relatively easily and survival is good. However, the majority of patients (for the time being) have to take these drugs for life. This is a major burden because half of the patients experience moderate to severe side effects, which reduce the quality of life.
Reduce side effects & reduce costs
There are indications that the dose of the medication can be safely reduced if the disease is stable. The lower dose reduces the chance and severity of side effects and improves the quality of life. In addition, dose reduction also means that patients need to take less medication. This reduces the cost of treatment (approximately €13,000-€70,000 per patient per year).
Patient-driven phase-out strategy
Under the leadership of Professor Nicole Blijlevens (Hematology) and researcher Charlotte Bekker (Pharmacy), the Department of Haematology and Pharmacy will develop and test a phasing out strategy in CML patients with whom the disease remains stable. Reduction means that the dose of medication will be lowered. The control and decision to reduce the dose is the patient's responsibility, and is therefore patient-driven. By giving the patient (in the home situation) his own direction, the researchers hope to motivate him/her to improve the lifelong use of medication. The disease remains stable, side effects diminish, the quality of life improves at lower drug costs.
The funding falls under the ZonMw programme Good Usage of Medicines.
Related news items
650,000 Euro funding for research into the phasing out of medication for leukaemia patients30 July 2020
With a 650,000 euro funding from ZonMw, researchers from the Haematology and Pharmacy departments can develop a medication phasing out strategy for patients with chronic myeloid leukaemia. This strategy will be tested in practice.read more
Increased role of patients after bowel cancer treatment30 July 2020
Approximately 14,000 patients get colorectal cancer every year. Almost all patients are operated on and monitored afterwards (follow-up). In 2019 Radboudumc started a new approach to follow-up research after the treatment of stage II/III colorectal cancer.read more
ERC Proof of Concept grant received by Ronald van Rij30 July 2020
Ronald van Rij, theme Infectious diseases and global health, received an ERC (European Research Council) Proof of Concept grant of 150,000 euros, in order to make arbovirus vaccines even safer.read more
Hypatia fellowship Call is open30 July 2020
The Hypatia fellowship round with the deadline 31 May has been canceled. Therefore, the next available deadline will be 27 September 2020. Radboudumc researchers are invited to scout young potentials to fill the strategic gaps within the research themes imbedded in RIHS and RIMLS.read more
Mihai Netea and colleagues published two papers back-to-back in The Journal of Clinical Investigation.29 July 2020
These back-to-back articles investigated the effect of BCG vaccination on trained immunity. The first article shows that BCG vaccination inhibits systemic inflammation, depending on gender. The second article demonstrates that the circadian rhythm influences the induction of trained immunity.read more
Genetic mutation reveals how coronavirus strikes TLR7 plays essential role in disease process28 July 2020
''Does a congenital immune defect play an important role in the defense against Coronavirus?'' This was published by Cas van der Made, Frank van der Veerdonk and Alexander Hoischen.read more